Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma.
BACKGROUND:First-line treatment for metastatic renal cell carcinoma (mRCC) is rapidly changing. It currently includes VEGF targeted therapies (TT), multi-target tyrosine kinase inhibitors (TKIs), mTOR inhibitors, and immunotherapy. To optimize outcomes for individual patients, genomic markers of res...
Main Authors: | David D Stenehjem, Andrew W Hahn, David M Gill, Daniel Albertson, Banumathy Gowrishankar, Joseph Merriman, Archana M Agarwal, Venkata Thodima, Erik B Harrington, Trang H Au, Benjamin L Maughan, Jane Houldsworth, Sumanta K Pal, Neeraj Agarwal |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2019-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0210415 |
Similar Items
-
Survival Outcomes and Tumor IMP3 Expression in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma
by: Srinivas K. Tantravahi, et al.
Published: (2015-01-01) -
CYP17 inhibitors in prostate cancer: latest evidence and clinical potential
by: Anitha B. Alex, et al.
Published: (2016-07-01) -
The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer.
by: Christopher H Lieu, et al.
Published: (2013-01-01) -
Radium-223 in metastatic castration resistant prostate cancer
by: Winston Vuong, et al.
Published: (2014-06-01) -
Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors
by: Sumanta Kumar Pal, et al.
Published: (2010-01-01)